KZ
KZIA.US Kazia Therapeutics Ltd ADR
- Market cap
- USD 75.6M
- P/E
- -
- P/B
- 3.24x
- ROE
- -96.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Dec 2025.
Is KZIA.US undervalued?
Graham numberThe Graham number of Kazia Therapeutics Ltd ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kazia Therapeutics Ltd ADR fundamental analysis
No fundamental analysis for Kazia Therapeutics Ltd ADR yet.
Kazia Therapeutics Ltd ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous…
Full company profileKazia Therapeutics Ltd ADR financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 2 quarters up to Dec 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kazia Therapeutics Ltd ADR annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.07M | 8.79M | 13.1K | 1.57K | 988K | 15.2M | 10.0K | 555.00 | 2.31M | 42.0K | - |
| Gross Profit | 4.07M | 8.79M | 13.1K | 1.57K | 988K | 15.2M | 10.0K | 555.00 | 2.31M | 42.0K | - |
| Operating Income | -12.8M | -10.9M | -12.5M | -8.38M | -12.2M | -6.38M | -25.4M | -24.1M | -28.5M | -14.2M | -36.3M |
| EBITDA | -11.7M | -9.44M | -13.0M | -7.71M | -11.1M | -5.11M | -23.5M | -22.3M | -26.6M | -13.3M | -36.3M |
| Net Income | -12.1M | -10.7M | -6.04M | -10.3M | -12.5M | -8.42M | -25.0M | -20.5M | -26.8M | -20.7M | -44.5M |
| EPS | -135 | -109 | -60 | -86 | -82 | -36 | -94 | -56 | -56 | -19 | -14 |
| Balance Sheet | |||||||||||
| Total Assets | 35.5M | 35.9M | 28.2M | 21.2M | 23.1M | 58.1M | 35.9M | 28.1M | 21.6M | 6.06M | 71.0M |
| Total Liabilities | 1.59M | 10.6M | 8.93M | 7.01M | 8.94M | 20.2M | 17.6M | 16.0M | 31.6M | 14.4M | 24.6M |
| Shareholders' Equity | 33.9M | 25.3M | 19.2M | 14.2M | 14.1M | 37.9M | 18.3M | 12.1M | -10.0M | -8.30M | 46.4M |
| Cash & Short-term Investments | 33.5M | 14.5M | 5.96M | 5.45M | 8.76M | 27.6M | 7.36M | 5.24M | 1.66M | 4.35M | 69.4M |
| Total Debt | 10.0K | 10.0K | 84.0K | 0.00 | - | - | 1.84M | 1.80M | 634K | 396K | 98.7K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.0M | -11.4M | -8.66M | -6.71M | -8.81M | -9.11M | -22.8M | -15.2M | -9.58M | -13.3M | -26.4M |
| Capital Expenditure | 525K | 11.6K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.28M |
| Free Cash Flow | -12.5M | -11.4M | -8.66M | -6.71M | -8.81M | -9.11M | -22.8M | -15.2M | -9.58M | -13.3M | - |
| Ratios | |||||||||||
| ROE | -35.5% | -42.1% | -31.4% | -72.3% | -88.3% | -22.2% | -136.9% | -169.8% | - | - | -96.0% |
| ROA | -34.0% | -29.7% | -21.4% | -48.5% | -54.1% | -14.5% | -69.7% | -72.9% | -124.1% | -341.6% | -62.7% |
| Net Profit Margin | -296.3% | -121.4% | -46,071.1% | -656,230.0% | -1,261.7% | -55.5% | -250,140.0% | -3,687,419.8% | -1,160.2% | -49,290.5% | - |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | - | - | 0.10x | 0.15x | - | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kazia Therapeutics Ltd ADR dividends
Kazia Therapeutics Ltd ADR has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Apr 17, 2025.
Who owns Kazia Therapeutics Ltd ADR
- Insiders 16.54%
- Institutions 36.07%
- Public & others 47.39%
- Shares outstanding 11.4M
- Free float 9.39M
Top funds holding KZIA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Exemplar Growth and Income Ser FD | 161K | 1.24% | +1.26% | Oct 2026 |
| ActivePassive International Equity ETF | 5.37K | 0.04% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 4.24K | 0.03% | 0.00% | Aug 2026 |
Top institutions holding KZIA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Boxer Capital Management, LLC | 560K | 4.33% | 0.00% | Jun 2026 |
| F.L.Putnam Investment Management | 415K | 3.21% | +191.26% | Jun 2026 |
| Bleichroeder LP | 400K | 3.09% | 0.00% | Jun 2026 |
| Ikarian Capital, LLC | 396K | 3.06% | 0.00% | Jun 2026 |
| Dauntless Investment Group, LLC | 354K | 2.74% | +343.69% | Jun 2026 |
| Stonepine Capital Management Llc | 345K | 2.67% | 0.00% | Jun 2026 |
| Point72 Asset Management, L.P. | 200K | 1.55% | +0.15% | Jun 2026 |
| Ensign Peak Advisors Inc | 111K | 0.86% | 0.00% | Jun 2026 |
| Millennium Management LLC | 101K | 0.78% | 0.00% | Jun 2026 |
| UBS Group AG | 81.1K | 0.63% | +481.96% | Jun 2026 |
| J. Goldman & Co LP | 68.5K | 0.53% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 61.6K | 0.48% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 57.1K | 0.44% | 0.00% | Jun 2026 |
| Barclays PLC | 57.0K | 0.44% | +137.51% | Jun 2026 |
| Susquehanna International Group, LLP | 50.6K | 0.39% | 0.00% | Jun 2026 |
| Cooperman Leon G | 50.0K | 0.39% | 0.00% | Jun 2026 |
| Westside Investment Management, Inc. | 47.6K | 0.37% | -5.63% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 46.6K | 0.36% | +4,560.60% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 44.2K | 0.34% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 31.2K | 0.24% | 0.00% | Jun 2026 |
Kazia Therapeutics Ltd ADR company profile
- Company name
- Kazia Therapeutics Ltd ADR
- Ticker
- KZIA.US
- Exchange
- USA Stocks
- Listed since
- Jan 6, 1999
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- June
- Address
- Three International Towers, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9472 4101
- Website
- kaziatherapeutics.com
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Ltd ADR management
5- Dr. John Edwin Friend II, M.D.Chief Executive Officer · born 1970
- Ms. Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAICCompany Secretary · born 1973
- Mr. Jeffrey BonacordaVP of Finance & Controller
- Mr. James E. LevineChief Financial Officer · born 1971
- Dr. Sudha RaoChief Scientific Officer